Background. Tafenoquine is an 8-aminoquinoline developed as a more effective
replacement for primaquine. In a previous dose-ranging study in Thailand, 3 tafenoquine …

Background Tafenoquine is an investigational 8-aminoquinoline for the prevention of
Plasmodium vivax relapse. Tafenoquine has a long half-life and the potential for more …

Abstract Background Treatment of Plasmodium vivax malaria requires the clearing of
asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared …

Background Clinical effectiveness of previous regimens to treat Plasmodium vivax infection
have been hampered by compliance. We aimed to assess the dose–response, safety, and …

WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax.
Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 …

We assessed monthly doses of tafenoquine for preventing Plasmodium vivax and multidrug-
resistant P. falciparum malaria. In a randomized, double-blind, placebo-controlled study, 205 …

Tafenoquine was used to treat Plasmodium vivax malaria cases who had previously failed
treatment with chloroquine and primaquine. Chloroquine was followed by a loading dose of …

Tafenoquine is being developed for radical cure and post-exposure prophylaxis of
Plasmodium vivax malaria. In an open-label study, 1512 Australian Defence Force …

Background Chloroquine has been recommended for Plasmodium vivax infections for> 60
years, but resistance is increasing. To guide future therapies, the cumulative benefits of …

Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use
of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase …